Long-term data confirmed the Zephyr Endobronchial Valve provided improvements over baseline in lung function and quality of life out to at least 24 months, and improvements in exercise capacity out to at least 18 months.
Long-term data confirmed the Zephyr Endobronchial Valve provided improvements over baseline in lung function and quality of life out to at least 24 months, and improvements in exercise capacity out to at least 18 months.
Read More
The Zephyr Endobronchial Valve is the first minimally-invasive device approved in the United States for treating patients with severe emphysema.
Read More
According to new data, emphysema patients treated with Zephyr Endobronchial Valves had improved breathing, quality of life, and activity, Pulmonx reports.
Read More
